



SC|H

Southern Cannabis Holdings

| See Beyond the Horizon |

SCH

Southern
Cannabis
Holdings

About us

- Diversified revenue streams
- Sector leaders
- 8 straight quarters of growth
- Profitable since 2019
- International footprint

SCH Group Companies



- 50% group revenue
- 7 clinics
- Specialists across pain, addiction, psychiatry, gastro-intestinal



- 25% group revenue
- Only specialist cannabis CRO in Australia
- leading RWE data collection platform
- 2 major ethics approved studies
- A dozen sub studies




- 10% group revenue
- More than 1Mil data points
- Most recognized and cited industry report
- 'go-to' source for industry expertise and insight
- more than 30 clients in sector




- 15% of group revenue
- Import and logistics
- Warehousing and supply
- Pharmacy consultancy

Q3 2020 FreshLeaf Analytics Report


Australian medicinal cannabis market – revenue (AUD)




Number of medical cannabis products available in the Australian market



Patient daily cannabinoid dose (mg)



Monthly patient spend (\$)



Whats next?

1

Continued rapid patient growth in Australia

2

Registered medicines coming

3

CBD becoming 'over the counter'

4

NZ goes recreational